Noninvasive vagus nerve stimulation affirms its potential to prevent migraine

Key clinical point: Noninvasive vagus nerve stimulation (nVNS) is an effective therapeutic option for preventing migraine.

Main finding: nVNS led to a greater mean reduction in monthly migraine days from baseline (3.12 days vs. 2.29 days; P = .2329) and a higher percentage of patients achieving ≥50% reduction in the number of migraine days (44.87% vs. 26.81%; P = .0481) compared to sham stimulation.

Study details: Findings are from the multicenter PREMIUM II trial wherein 231 adults with episodic or chronic migraine (with or without aura) were randomly assigned to receive nVNS (n = 114) or sham stimulation (n = 117) over 12 weeks. Of these, 113 (nVNS, n = 56; sham, n = 57) constituted the modified intention-to-treat population.

,

Disclosures: The study was sponsored by electroCore, Inc. Some of the authors, including the lead author, reported serving as a consultant/advisor/speaker for and receiving research grants from various organizations, including electroCore. E Liebler is an employee and stockholder of electroCore.

Source: Najib U et al. Cephalalgia. 2022  (Jan 9). Doi: 10.1177/03331024211068813.